WINTON GROUP Ltd Has $1.11 Million Stock Holdings in BioMarin Pharmaceutical Inc. $BMRN

WINTON GROUP Ltd cut its stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 84.8% during the 4th quarter, Holdings Channel.com reports. The firm owned 18,720 shares of the biotechnology company’s stock after selling 104,754 shares during the period. WINTON GROUP Ltd’s holdings in BioMarin Pharmaceutical were worth $1,113,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently modified their holdings of the company. DNB Asset Management AS lifted its position in BioMarin Pharmaceutical by 13.8% during the third quarter. DNB Asset Management AS now owns 1,274,284 shares of the biotechnology company’s stock worth $69,015,000 after acquiring an additional 154,954 shares during the last quarter. New York Life Investment Management LLC bought a new position in shares of BioMarin Pharmaceutical during the third quarter worth approximately $1,071,000. Assenagon Asset Management S.A. lifted its holdings in BioMarin Pharmaceutical by 312.4% during the 4th quarter. Assenagon Asset Management S.A. now owns 1,419,067 shares of the biotechnology company’s stock worth $84,335,000 after purchasing an additional 1,074,929 shares during the last quarter. Braidwell LP acquired a new stake in BioMarin Pharmaceutical during the 3rd quarter worth approximately $28,596,000. Finally, Perpetual Ltd boosted its stake in BioMarin Pharmaceutical by 425.7% in the 4th quarter. Perpetual Ltd now owns 25,621 shares of the biotechnology company’s stock valued at $1,523,000 after purchasing an additional 20,747 shares during the period. Institutional investors and hedge funds own 98.71% of the company’s stock.

Analysts Set New Price Targets

BMRN has been the topic of a number of research reports. Truist Financial raised BioMarin Pharmaceutical to a “strong-buy” rating in a report on Wednesday, March 25th. Bank of America dropped their target price on BioMarin Pharmaceutical from $85.00 to $80.00 and set a “buy” rating for the company in a report on Tuesday, May 19th. Citigroup assumed coverage on shares of BioMarin Pharmaceutical in a research note on Tuesday, May 19th. They issued a “buy” rating and a $75.00 price target on the stock. Oppenheimer lowered their price target on shares of BioMarin Pharmaceutical from $98.00 to $95.00 and set an “outperform” rating on the stock in a research report on Tuesday, February 24th. Finally, Loop Capital set a $105.00 price objective on shares of BioMarin Pharmaceutical in a research note on Monday, March 2nd. Two analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and seven have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $88.67.

BioMarin Pharmaceutical Price Performance

BioMarin Pharmaceutical stock opened at $57.91 on Wednesday. The firm has a market cap of $11.19 billion, a PE ratio of 42.27, a price-to-earnings-growth ratio of 0.43 and a beta of 0.25. The company has a debt-to-equity ratio of 0.23, a current ratio of 5.81 and a quick ratio of 4.20. The stock’s fifty day moving average price is $54.37 and its two-hundred day moving average price is $56.40. BioMarin Pharmaceutical Inc. has a one year low of $49.26 and a one year high of $66.28.

Insider Activity

In related news, EVP Gregory R. Friberg sold 3,281 shares of the firm’s stock in a transaction on Thursday, May 7th. The stock was sold at an average price of $53.85, for a total value of $176,681.85. Following the transaction, the executive vice president owned 51,818 shares in the company, valued at approximately $2,790,399.30. This trade represents a 5.95% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.85% of the company’s stock.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.